Multicenter Study

4

Review clinical trials related to Multicenter Study. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction

To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.

Participants needed: 300
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Qianfoshan HospitalUpdated: Jun 1, 2026Locations: 1
Eligibility criteria

Female and Male patients aged 18-80 years [+1]

Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cereb... [+4]

Status: Recruiting

The Epidemiology of Suicide Attempts and Suicidal Thoughts in Flanders

The objective of this study is to collect data in Flanders on the incidence of suicide attempts and suicidal ideation across various healthcare settings. The study also aims to assess the proportion of individuals who receive adequate aftercare following a suicide attempt and to systematically document the methods and means used in suicidal behavior.

Participants needed: 50,000
Trial details
Age: 12+Biological sex: AllType: ObservationalSponsor: University Hospital, GhentUpdated: Jun 15, 2025Locations: 33Duration: 1 Day
Eligibility criteria

Everyone who is admitted alive to the emergency department after a suicide attem... [+1]

Accidental overdose, e.g., someone taking medication for a medical condition wit... [+3]

Status: Recruiting

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Previous studies have reported the efficacy of Bacillus Calmette-Guérin (BCG) combined with other drugs for the treatment of bladder cancer. However, research on the combination of tislelizumab and BCG for bladder cancer treatment has largely been retrospective. Currently, ongoing clinical trials have not discussed the effectiveness of PD-1/PD-L1 inhibitors combined with BCG instillation in reducing postoperative recurrence in intermediate-risk NMIBC. Therefore, this study aims to explore the clinical efficacy and safety of tislelizumab combined with BCG in the treatment of intermediate and high-risk NMIBC. For this purpose, investigators have established strict screening criteria to include eligible patients in the study and have recruited suitable patients from multiple medical centers.Investigators have also developed a meticulous implementation process and follow-up considerations, hoping to better verify the clinical efficacy and safety of the combined use of these two drugs.

Participants needed: 76
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Fujian Medical University Union HospitalUpdated: Jun 4, 2024Locations: 1
Eligibility criteria

Voluntary participation in the trial with signed informed consent; [+4]

Concurrent urogenital system tumors or tumors in other organs; [+11]

Status: Recruiting

Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging

The incidence of Heart failure with preserved ejection fraction (HFpEF) in Heart failure patients increases rapidly. However, the current clinical awareness is insufficient, and the cardiac structural and functional injury are not well understood. It is difficult to recognize the subclinical changes of the cardiac in the early stage with conventional imaging techniques, and it is common to ignore the existence of the clinical alterations. This study aimed to investigate the cardiac features, early diagnosis and risk factors of HFpEF patients, based on the multi-modality (Magnetic resonance imaging- nuclear medicine imaging- echocardiography) imaging and multicenter study, combined with large data and artificial intelligence. This study will provide deep insights into the HFpEF in multicenter population.

Participants needed: 1,000
Trial details
Biological sex: AllType: ObservationalSponsor: Chinese Academy of Medical Sciences, Fuwai HospitalUpdated: Apr 18, 2022Locations: 1Duration: 8 Years
Eligibility criteria

left ventricular ejection fraction (LVEF)≥50%; [+3]

Special types of cardiomyopathy, including hypertrophic cardiomyopathy, restrict... [+5]